These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32580205)

  • 21. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
    Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
    Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the G2019S LRRK2 mutation common in all southern European populations?
    Papapetropoulos S; Adi N; Shehadeh L; Bishopric N; Singer C; Argyriou AA; Chroni E
    J Clin Neurosci; 2008 Sep; 15(9):1027-30. PubMed ID: 18617409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.
    Li Y; Ikeda A; Yoshino H; Oyama G; Kitani M; Daida K; Hayashida A; Ogaki K; Yoshida K; Kimura T; Nakayama Y; Ito H; Sugeno N; Aoki M; Miyajima H; Kimura K; Ueda N; Watanabe M; Urabe T; Takanashi M; Funayama M; Nishioka K; Hattori N
    J Hum Genet; 2020 Sep; 65(9):771-781. PubMed ID: 32398759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
    Bryant N; Malpeli N; Ziaee J; Blauwendraat C; Liu Z; ; West AB
    Hum Mol Genet; 2021 Apr; 30(6):454-466. PubMed ID: 33640967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-motor symptoms in Chinese Parkinson's disease patients with and without LRRK2 G2385R and R1628P variants.
    Li DW; Gu Z; Wang C; Ma J; Tang BS; Chen SD; Chan P
    J Neural Transm (Vienna); 2015 May; 122(5):661-7. PubMed ID: 25062988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of the worldwide distribution of
    El Otmani H; Daghi M; Tahiri Jouti N; Lesage S
    Neurodegener Dis Manag; 2023 Dec; 13(6):335-350. PubMed ID: 38305913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse.
    Giesert F; Glasl L; Zimprich A; Ernst L; Piccoli G; Stautner C; Zerle J; Hölter SM; Vogt Weisenhorn DM; Wurst W
    Neurobiol Dis; 2017 Sep; 105():179-193. PubMed ID: 28576705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LRRK2 G2385R and R1628P mutations are associated with an increased risk of Parkinson's disease in the Malaysian population.
    Gopalai AA; Lim SY; Chua JY; Tey S; Lim TT; Mohamed Ibrahim N; Tan AH; Eow GB; Abdul Aziz Z; Puvanarajah SD; Viswanathan S; Looi I; Lim SK; Tan LP; Chong YB; Tan CT; Zhao Y; Tan EK; Ahmad-Annuar A
    Biomed Res Int; 2014; 2014():867321. PubMed ID: 25243190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic analysis of LRRK2 in Parkinson's disease in Han Chinese population.
    Zhang JR; Jin H; Li K; Mao CJ; Yang YP; Wang F; Gu CC; Zhang HJ; Chen J; Liu CF
    Neurobiol Aging; 2018 Dec; 72():187.e5-187.e10. PubMed ID: 30049590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.
    Latourelle JC; Sun M; Lew MF; Suchowersky O; Klein C; Golbe LI; Mark MH; Growdon JH; Wooten GF; Watts RL; Guttman M; Racette BA; Perlmutter JS; Ahmed A; Shill HA; Singer C; Goldwurm S; Pezzoli G; Zini M; Saint-Hilaire MH; Hendricks AE; Williamson S; Nagle MW; Wilk JB; Massood T; Huskey KW; Laramie JM; DeStefano AL; Baker KB; Itin I; Litvan I; Nicholson G; Corbett A; Nance M; Drasby E; Isaacson S; Burn DJ; Chinnery PF; Pramstaller PP; Al-hinti J; Moller AT; Ostergaard K; Sherman SJ; Roxburgh R; Snow B; Slevin JT; Cambi F; Gusella JF; Myers RH
    BMC Med; 2008 Nov; 6():32. PubMed ID: 18986508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical features of LRRK2-associated Parkinson's disease].
    Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Landscape of Monogenic Parkinson's Disease in Populations of Non-European Ancestry: A Narrative Review.
    Koros C; Bougea A; Simitsi AM; Papagiannakis N; Angelopoulou E; Pachi I; Antonelou R; Bozi M; Stamelou M; Stefanis L
    Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
    Hatano T; Funayama M; Kubo SI; Mata IF; Oji Y; Mori A; Zabetian CP; Waldherr SM; Yoshino H; Oyama G; Shimo Y; Fujimoto KI; Oshima H; Kunii Y; Yabe H; Mizuno Y; Hattori N
    Neurobiol Aging; 2014 Nov; 35(11):2656.e17-2656.e23. PubMed ID: 24973808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LRRK2: Genetic mechanisms vs genetic subtypes.
    Mata I; Salles P; Cornejo-Olivas M; Saffie P; Ross OA; Reed X; Bandres-Ciga S
    Handb Clin Neurol; 2023; 193():133-154. PubMed ID: 36803807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRRK2 mutations in Parkinson's disease: confirmation of a gender effect in the Italian population.
    Cilia R; Siri C; Rusconi D; Allegra R; Ghiglietti A; Sacilotto G; Zini M; Zecchinelli AL; Asselta R; Duga S; Paganoni AM; Pezzoli G; Seia M; Goldwurm S
    Parkinsonism Relat Disord; 2014 Aug; 20(8):911-4. PubMed ID: 24816003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.